ArticleThe oncologist2026

Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis.

Federico Nichetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.